Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
1
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
93
.8
%
1988
CLO
1
Ltd.
2022-1A
D1R,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4176%,
10/15/39
(144A)
$
1,000,000
$
1,006,497
522
Funding
CLO
Ltd.
2020-6A
DR,
CME
Term
SOFR
3
Month
+
3.4116%,
7.7306%,
10/23/34
(144A)
13,000,000
13,016,500
AB
BSL
CLO
1
Ltd.
2020-1A
DR,
CME
Term
SOFR
3
Month
+
3.4500%,
7.7676%,
1/15/35
(144A)
2,000,000
2,013,865
AB
BSL
CLO
2
Ltd.
2021-2A
D,
CME
Term
SOFR
3
Month
+
3.6116%,
7.9292%,
4/15/34
(144A)
3,000,000
3,020,395
AGL
CLO
14
Ltd.
2021-14A
DR,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1755%,
12/2/34
(144A)
7,250,000
7,250,074
AGL
CLO
16
Ltd.
2021-16A
DR,
CME
Term
SOFR
3
Month
+
2.4000%,
6.7255%,
1/20/35
(144A)
1,900,000
1,899,970
AGL
CLO
21
Ltd.
2022-21A
D2R,
CME
Term
SOFR
3
Month
+
4.4000%,
8.7255%,
10/21/37
(144A)
2,200,000
2,208,149
AGL
CLO
37
Ltd.
2024-37A
D1,
CME
Term
SOFR
3
Month
+
2.6500%,
6.9820%,
4/22/38
(144A)
4,000,000
4,009,601
Allegany
Park
CLO
Ltd.
2019-1A
DR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4255%,
1/20/35
(144A)
2,000,000
2,000,000
Allegro
CLO
XII
Ltd.
2020-1A
D1R,
CME
Term
SOFR
3
Month
+
3.5000%,
7.8255%,
7/21/37
(144A)
4,500,000
4,527,725
Allegro
CLO
XIX
Ltd.
2025-1A
D2,
CME
Term
SOFR
3
Month
+
4.0500%,
8.3724%,
4/17/38
(144A)
5,700,000
5,735,111
AMMC
CLO
24
Ltd.
2021-24A
DR,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2755%,
1/20/35
(144A)
3,000,000
3,002,105
AMMC
CLO
27
Ltd.
2022-27A
DR,
CME
Term
SOFR
3
Month
+
2.7000%,
7.0255%,
1/20/37
(144A)
11,040,000
11,078,138
Anchorage
Capital
CLO
16
Ltd.
2020-16A
D1R2,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2255%,
1/19/38
(144A)
9,250,000
9,319,372
Anchorage
Capital
CLO
7
Ltd.
2015-7A
DR3,
CME
Term
SOFR
3
Month
+
3.8000%,
8.1138%,
4/28/37
(144A)
1,000,000
1,005,656
Annisa
CLO
Ltd.
2016-2A
ERR,
CME
Term
SOFR
3
Month
+
6.9270%,
11.2525%,
7/20/31
(144A)
3,000,000
3,022,131
Apidos
CLO
XLII
Ltd.
2022-42A
D1R,
CME
Term
SOFR
3
Month
+
2.4500%,
6.7755%,
4/20/38
(144A)
10,000,000
10,029,150
Apidos
CLO
XXXVIII
2021-38A
D,
CME
Term
SOFR
3
Month
+
3.2116%,
7.5371%,
1/21/34
(144A)
8,360,000
8,415,295
Ares
LVI
CLO
Ltd.
2020-56A
D1R2,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1685%,
1/25/38
(144A)
3,985,000
3,991,533
Ares
LXII
CLO
Ltd.
2021-62A
D,
CME
Term
SOFR
3
Month
+
3.3616%,
7.6801%,
1/25/34
(144A)
3,000,000
3,013,814
Ares
LXIV
CLO
Ltd.
2022-64A
DR,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5675%,
10/24/39
(144A)
2,500,000
2,507,928
Ares
LXV
CLO
Ltd.
2022-65A
D,
CME
Term
SOFR
3
Month
+
3.6500%,
7.9685%,
7/25/34
(144A)
10,750,000
10,811,379
Ares
XLIII
CLO
Ltd.
2017-43A
D2R2,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4175%,
1/15/38
(144A)
7,000,000
7,073,397
Ares
XXXIX
CLO
Ltd.
2016-39A
DR3,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5790%,
7/18/37
(144A)
10,000,000
10,028,256
Atlas
Senior
Loan
Fund
XVI
Ltd.
2021-16A
D,
CME
Term
SOFR
3
Month
+
3.9616%,
8.2871%,
1/20/34
(144A)
8,400,000
8,401,980
Bain
Capital
Credit
CLO
Ltd.
2021-2A
DR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4178%,
7/16/34
(144A)
4,750,000
4,755,547
Bain
Capital
Credit
CLO
Ltd.
2019-3A
DRR,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1255%,
10/21/34
(144A)
9,000,000
9,022,951
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
2
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Bain
Capital
Credit
CLO
Ltd.
2020-3A
DRR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4190%,
10/23/34
(144A)
$
5,845,000
$
5,850,823
Bain
Capital
Credit
CLO
Ltd.
2024-4A
D1,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4190%,
10/23/37
(144A)
2,000,000
2,014,249
Ballyrock
CLO
25
Ltd.
2023-25A
C1R,
CME
Term
SOFR
3
Month
+
2.6000%,
6.9185%,
1/25/38
(144A)
9,500,000
9,518,280
Ballyrock
CLO
28
Ltd.
2024-28A
C1,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1255%,
1/20/38
(144A)
4,790,000
4,813,928
Barings
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.1616%,
7.4801%,
4/25/34
(144A)
3,990,000
4,003,956
Barings
CLO
Ltd.
2020-4A
D2R,
CME
Term
SOFR
3
Month
+
5.0000%,
9.3255%,
10/20/37
(144A)
5,000,000
5,037,524
Benefit
Street
Partners
CLO
XXV
Ltd.
2021-25A
DR,
CME
Term
SOFR
3
Month
+
2.3500%,
6.6675%,
1/15/35
(144A)
10,000,000
10,028,623
Benefit
Street
Partners
CLO
XXVI
Ltd.
2022-26A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
7/20/37
(144A)
4,750,000
4,770,163
Bethpage
Park
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.2116%,
7.5292%,
10/15/36
(144A)
1,500,000
1,500,725
Birch
Grove
CLO
11
Ltd.
2024-11A
D1,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4320%,
1/22/38
(144A)
8,000,000
8,057,609
Birch
Grove
CLO
2
Ltd.
2021-2A
D1R,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4755%,
10/19/37
(144A)
3,000,000
3,002,911
Birch
Grove
CLO
3
Ltd.
2021-3A
D1R,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1755%,
1/19/38
(144A)
2,750,000
2,753,161
Birch
Grove
CLO
3
Ltd.
2021-3A
D2R,
CME
Term
SOFR
3
Month
+
3.8500%,
8.1755%,
1/19/38
(144A)
5,000,000
5,002,874
Birch
Grove
CLO
6
Ltd.
2023-6A
D1R,
CME
Term
SOFR
3
Month
+
3.1500%,
7.5209%,
7/20/38
(144A)
10,000,000
10,028,051
BlueMountain
CLO
XXV
Ltd.
2019-25A
D1RR,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5675%,
1/15/38
(144A)
12,500,000
12,543,774
BlueMountain
CLO
XXVI
Ltd.
2019-26A
D1R,
CME
Term
SOFR
3
Month
+
3.7616%,
8.0871%,
10/20/34
(144A)
2,700,000
2,717,545
BlueMountain
CLO
XXVI
Ltd.
2019-26A
D2R,
CME
Term
SOFR
3
Month
+
4.6316%,
8.9571%,
10/20/34
(144A)
4,500,000
4,520,151
BlueMountain
CLO
XXXII
Ltd.
2021-32A
DR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4176%,
10/15/34
(144A)
19,250,000
19,256,225
BlueMountain
CLO
XXXIV
Ltd.
2022-34A
D,
CME
Term
SOFR
3
Month
+
3.7500%,
8.0755%,
4/20/35
(144A)
9,210,000
9,244,497
Canyon
Capital
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.3616%,
7.6792%,
4/15/34
(144A)
9,000,000
9,057,590
Canyon
Capital
CLO
Ltd.
2021-2A
D,
CME
Term
SOFR
3
Month
+
3.6116%,
7.9292%,
4/15/34
(144A)
5,250,000
5,281,700
Canyon
Capital
CLO
Ltd.
2019-2A
DR2,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1675%,
10/15/34
(144A)
10,000,000
9,880,356
Canyon
Capital
CLO
Ltd.
2019-1A
D1RR,
CME
Term
SOFR
3
Month
+
3.6500%,
7.9675%,
7/15/37
(144A)
2,600,000
2,606,488
Canyon
CLO
Ltd.
2020-2A
DR2,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2676%,
10/15/34
(144A)
5,000,000
5,000,768
Canyon
CLO
Ltd.
2025-1A
D1,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0361%,
4/15/38
(144A)
3,000,000
3,010,253
Capital
Four
US
CLO
I
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.8816%,
8.2106%,
1/18/35
(144A)
7,430,000
7,455,002
Carlyle
US
CLO
2024-4A
D,
CME
Term
SOFR
3
Month
+
3.2000%,
7.5255%,
7/20/37
(144A)
1,000,000
1,004,794
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
3
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Carlyle
US
CLO
Ltd.
2021-9A
DR,
CME
Term
SOFR
3
Month
+
3.0500%,
7.3685%,
10/20/34
(144A)
$
3,000,000
$
2,999,981
Carlyle
US
CLO
Ltd.
2020-2A
CR,
CME
Term
SOFR
3
Month
+
3.4616%,
7.7801%,
1/25/35
(144A)
7,600,000
7,640,000
Carlyle
US
CLO
Ltd.
2023-4A
D,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4185%,
10/25/36
(144A)
7,700,000
7,780,296
Carlyle
US
CLO
Ltd.
2017-2A
D2R2,
CME
Term
SOFR
3
Month
+
4.7500%,
9.0755%,
7/20/37
(144A)
6,750,000
6,797,137
Carlyle
US
CLO
Ltd.
2021-7A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3176%,
4/15/40
(144A)
5,300,000
5,314,339
CBAMR
Ltd.
2018-8A
DR,
CME
Term
SOFR
3
Month
+
4.0000%,
8.3176%,
7/15/37
(144A)
6,580,000
6,591,065
Cedar
Funding
IV
CLO
Ltd.
2014-4A
DR3,
CME
Term
SOFR
3
Month
+
3.3000%,
7.6190%,
1/23/38
(144A)
5,000,000
5,006,138
Cedar
Funding
VI
CLO
Ltd.
2016-6A
ARR,
CME
Term
SOFR
3
Month
+
1.3116%,
5.6371%,
4/20/34
(144A)
5,740,000
5,743,138
CIFC
Funding
2021-2A
D,
CME
Term
SOFR
3
Month
+
2.9116%,
7.2292%,
4/15/34
(144A)
6,000,000
6,029,686
CIFC
Funding
2014-V
Ltd.
2014-5A
ER3,
CME
Term
SOFR
3
Month
+
7.5000%,
11.8224%,
7/17/37
(144A)
2,000,000
2,034,015
CIFC
Funding
2020-IV
Ltd.
2020-4A
DR,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1175%,
1/15/40
(144A)
3,850,000
3,859,533
CIFC
Funding
Ltd.
2014-4RA
CRR,
CME
Term
SOFR
3
Month
+
2.6000%,
6.9224%,
1/17/35
(144A)
6,050,000
6,058,198
CIFC
Funding
Ltd.
2014-4RA
DRR,
CME
Term
SOFR
3
Month
+
5.8000%,
10.1224%,
1/17/35
(144A)
9,000,000
8,978,508
CIFC
Funding
Ltd.
2021-3A
D,
CME
Term
SOFR
3
Month
+
3.2616%,
7.5792%,
7/15/36
(144A)
5,050,000
5,079,652
CIFC
Funding
Ltd.
2014-5A
D1R3,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5724%,
7/17/37
(144A)
5,000,000
5,019,840
CIFC
Funding
Ltd.
2021-5A
D1R,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0675%,
1/15/38
(144A)
5,000,000
5,008,163
Clover
CLO
LLC
2021-3A
DR,
CME
Term
SOFR
3
Month
+
2.5500%,
6.8685%,
1/25/35
(144A)
2,000,000
2,005,416
CQS
US
CLO
Ltd.
2023-3A
D,
CME
Term
SOFR
3
Month
+
4.2000%,
8.5185%,
1/25/37
(144A)
1,150,000
1,156,677
Crown
City
CLO
II
2020-2A
CR,
CME
Term
SOFR
3
Month
+
3.3500%,
7.6755%,
4/20/35
(144A)
12,200,000
12,270,756
Crown
City
CLO
III
2021-1A
C,
CME
Term
SOFR
3
Month
+
3.5616%,
7.8871%,
7/20/34
(144A)
5,250,000
5,282,117
Crown
City
CLO
IV
2022-4A
C1R,
CME
Term
SOFR
3
Month
+
4.5000%,
8.8255%,
4/20/37
(144A)
5,000,000
5,016,144
Crown
City
CLO
V
2023-5A
C1AR,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4255%,
4/20/37
(144A)
4,750,000
4,779,759
Crown
City
CLO
VI
2024-6A
E,
CME
Term
SOFR
3
Month
+
6.5000%,
10.8176%,
7/15/37
(144A)
3,250,000
3,302,700
Crown
Point
CLO
11
Ltd.
2021-11A
D2R,
CME
Term
SOFR
3
Month
+
4.2500%,
8.5724%,
2/28/38
(144A)
5,000,000
5,033,410
Dryden
102
CLO
Ltd.
2023-102A
D,
CME
Term
SOFR
3
Month
+
4.5500%,
8.8675%,
10/15/36
(144A)
4,000,000
4,034,621
Dryden
68
CLO
Ltd.
2019-68A
DR,
CME
Term
SOFR
3
Month
+
3.6116%,
7.9292%,
7/15/35
(144A)
6,500,000
6,500,488
Dryden
83
CLO
Ltd.
2020-83A
ER,
CME
Term
SOFR
3
Month
+
6.3200%,
10.6490%,
4/18/37
(144A)
12,325,000
12,475,790
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
4
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Dryden
86
CLO
Ltd.
2020-86A
DR,
CME
Term
SOFR
3
Month
+
3.4616%,
7.7840%,
7/17/34
(144A)
$
6,000,000
$
6,002,697
Dryden
98
CLO
Ltd.
2022-98A
D,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4255%,
4/20/35
(144A)
7,300,000
7,300,103
Eaton
Vance
CLO
Ltd.
2019-1A
D1R2,
CME
Term
SOFR
3
Month
+
3.3500%,
7.6676%,
7/15/37
(144A)
8,395,000
8,422,501
Elevation
CLO
Ltd.
2018-3A
DR,
CME
Term
SOFR
3
Month
+
3.8716%,
8.1901%,
1/25/35
(144A)
7,900,000
7,900,682
Elmwood
CLO
14
Ltd.
2022-1A
D,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4755%,
4/20/35
(144A)
4,250,000
4,274,436
Elmwood
CLO
17
Ltd.
2022-4A
D1R,
CME
Term
SOFR
3
Month
+
3.0500%,
7.3724%,
7/17/37
(144A)
15,000,000
15,066,390
Elmwood
CLO
18
Ltd.
2022-5A
D1RR,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2724%,
7/17/37
(144A)
14,000,000
14,063,609
Elmwood
CLO
30
Ltd.
2024-6A
D2,
CME
Term
SOFR
3
Month
+
4.2500%,
8.5724%,
7/17/37
(144A)
5,500,000
5,555,408
Elmwood
CLO
31
Ltd.
2024-7A
D2,
CME
Term
SOFR
3
Month
+
4.2000%,
8.5224%,
7/17/37
(144A)
2,500,000
2,525,488
Elmwood
CLO
37
Ltd.
2024-13A
D2,
CME
Term
SOFR
3
Month
+
3.7500%,
8.0724%,
1/17/38
(144A)
2,000,000
2,019,108
Elmwood
CLO
I
Ltd.
2019-1A
DRR,
CME
Term
SOFR
3
Month
+
3.7500%,
8.0755%,
4/20/37
(144A)
6,000,000
6,052,840
Elmwood
CLO
II
Ltd.
2019-2A
D1RR,
CME
Term
SOFR
3
Month
+
3.0500%,
7.3755%,
10/20/37
(144A)
4,870,000
4,890,817
Elmwood
CLO
III
Ltd.
2019-3A
DRR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4290%,
7/18/37
(144A)
14,000,000
14,043,319
Elmwood
CLO
IX
Ltd.
2021-2A
D1R,
CME
Term
SOFR
3
Month
+
2.6500%,
6.9755%,
4/20/38
(144A)
1,500,000
1,502,878
Elmwood
CLO
V
Ltd.
2020-2A
D1RR,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4755%,
10/20/37
(144A)
1,000,000
1,004,070
Elmwood
CLO
VI
Ltd.
2020-3A
D1RR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4290%,
7/18/37
(144A)
8,200,000
8,232,181
Elmwood
CLO
VII
Ltd.
2020-4A
D2RR,
CME
Term
SOFR
3
Month
+
4.3500%,
8.6724%,
10/17/37
(144A)
2,500,000
2,524,740
Elmwood
CLO
XII
Ltd.
2021-5A
D1R,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4176%,
10/15/37
(144A)
17,000,000
17,070,297
Empower
CLO
Ltd.
2022-1A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
10/20/37
(144A)
4,000,000
4,025,020
Generate
CLO
10
Ltd.
2022-10A
D1R,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1820%,
1/22/38
(144A)
5,000,000
4,962,812
Generate
CLO
11
Ltd.
2023-11A
D1R,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5755%,
10/20/37
(144A)
4,500,000
4,518,141
Generate
CLO
16
Ltd.
2024-16A
D2,
CME
Term
SOFR
3
Month
+
4.5000%,
8.8255%,
7/20/37
(144A)
3,500,000
3,505,080
Generate
CLO
21
Ltd.
2025-21A
D1,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4064%,
7/25/38
(144A)
2,500,000
2,521,551
Generate
CLO
5
Ltd.
5A
D1R,
CME
Term
SOFR
3
Month
+
3.7000%,
8.0320%,
7/22/37
(144A)
7,500,000
7,519,271
Generate
CLO
7
Ltd.
7A
D1R,
CME
Term
SOFR
3
Month
+
4.0000%,
8.3320%,
4/22/37
(144A)
4,227,000
4,235,643
Generate
CLO
9
Ltd.
9A
D1R,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4255%,
1/20/38
(144A)
7,000,000
7,023,060
GoldenTree
Loan
Management
US
CLO
14
Ltd.
2022-14A
DR,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
7/20/37
(144A)
1,950,000
1,954,818
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
5
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Halsey
Point
CLO
I
Ltd.
2019-1A
D1R,
CME
Term
SOFR
3
Month
+
3.8000%,
8.1255%,
10/20/37
(144A)
$
5,000,000
$
5,003,018
Halseypoint
CLO
5
Ltd.
2021-5A
D,
CME
Term
SOFR
3
Month
+
3.7616%,
8.0716%,
1/30/35
(144A)
2,000,000
2,007,931
Hayfin
US
XII
Ltd.
2020-12A
DR,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5755%,
1/20/38
(144A)
4,340,000
4,369,669
HPS
Loan
Management
Ltd.
15A-19
DR,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4820%,
1/22/35
(144A)
2,500,000
2,512,767
Invesco
CLO
Ltd.
2021-2A
D,
CME
Term
SOFR
3
Month
+
3.1616%,
7.4792%,
7/15/34
(144A)
1,000,000
995,000
KKR
CLO
27
Ltd.
27A
D1R2,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2176%,
1/15/35
(144A)
4,650,000
4,665,943
KKR
CLO
27
Ltd.
27A
D2R2,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4175%,
1/15/35
(144A)
4,500,000
4,502,988
KKR
CLO
35
Ltd.
35A
DR,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0755%,
1/20/38
(144A)
8,900,000
8,784,199
Madison
Park
Funding
LIV
Ltd.
2022-54A
D2R,
CME
Term
SOFR
3
Month
+
4.2500%,
8.5755%,
10/21/37
(144A)
10,000,000
10,006,119
Madison
Park
Funding
LIX
Ltd.
2021-59A
D1AR,
CME
Term
SOFR
3
Month
+
3.3000%,
7.6290%,
4/18/37
(144A)
2,500,000
2,515,195
Madison
Park
Funding
LVII
Ltd.
2022-57A
DR,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2638%,
7/27/34
(144A)
2,000,000
2,000,803
Madison
Park
Funding
XLV
Ltd.
2020-45A
DRR,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2176%,
7/15/34
(144A)
19,400,000
19,407,603
Madison
Park
Funding
XLVI
Ltd.
2020-46A
DRR,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0675%,
10/15/34
(144A)
7,250,000
7,167,433
Madison
Park
Funding
XXXI
Ltd.
2018-31A
D1R,
CME
Term
SOFR
3
Month
+
3.3000%,
7.6190%,
7/23/37
(144A)
5,650,000
5,695,164
Madison
Park
Funding
XXXIII
Ltd.
2019-33A
DR,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4176%,
10/15/32
(144A)
1,075,000
1,080,370
Madison
Park
Funding
XXXIV
Ltd.
2019-34A
D1RR,
CME
Term
SOFR
3
Month
+
3.3500%,
7.6678%,
10/16/37
(144A)
3,000,000
3,010,306
Madison
Park
Funding
XXXIX
Ltd.
2021-39A
DR,
CME
Term
SOFR
3
Month
+
3.2000%,
7.5320%,
10/22/34
(144A)
17,050,000
17,101,072
Magnetite
XIX
Ltd.
2017-19A
DRR,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0724%,
4/17/34
(144A)
5,000,000
4,999,801
Magnetite
Xlii
Ltd.
2024-42A
D2,
CME
Term
SOFR
3
Month
+
3.9500%,
8.2685%,
1/25/38
(144A)
2,500,000
2,524,768
Magnetite
XLIV
Ltd.
2024-44A
D1,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1675%,
10/15/37
(144A)
7,500,000
7,526,782
Magnetite
XLVII
Ltd.
2024-47A
D1,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1685%,
1/25/38
(144A)
1,000,000
1,006,329
Magnetite
XXVI
Ltd.
2020-26A
D1R2,
CME
Term
SOFR
3
Month
+
2.5000%,
6.8185%,
1/25/38
(144A)
3,000,000
2,993,949
Magnetite
XXXIV
Ltd.
2023-34A
D1R,
CME
Term
SOFR
3
Month
+
2.5500%,
6.8676%,
1/15/38
(144A)
2,500,000
2,508,074
Magnetite
XXXIX
Ltd.
2023-39A
D1R,
CME
Term
SOFR
3
Month
+
2.7000%,
7.0185%,
1/25/37
(144A)
1,000,000
1,002,704
Magnetite
XXXIX
Ltd.
2023-39A
D2R,
CME
Term
SOFR
3
Month
+
3.9000%,
8.2185%,
1/25/37
(144A)
4,000,000
4,037,363
Magnetite
XXXVI
Ltd.
2023-36A
DR,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1185%,
7/25/38
(144A)
9,750,000
9,761,139
Mariner
CLO
LLC
2016-3A
D1R3,
CME
Term
SOFR
3
Month
+
4.1500%,
8.4690%,
1/23/37
(144A)
3,750,000
3,759,213
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
6
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Meacham
Park
CLO
Ltd.
2024-1A
D,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2255%,
10/20/37
(144A)
$
1,000,000
$
1,003,650
Morgan
Stanley
Eaton
Vance
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.3616%,
7.6806%,
10/20/34
(144A)
2,640,000
2,655,829
Morgan
Stanley
Eaton
Vance
CLO
Ltd.
2022-17A
D1R,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4755%,
10/20/37
(144A)
1,325,000
1,330,363
Neuberger
Berman
CLO
XVII
Ltd.
2014-17A
D2R3,
CME
Term
SOFR
3
Month
+
4.5000%,
8.8320%,
7/22/38
(144A)
4,000,000
4,038,692
Neuberger
Berman
Loan
Advisers
CLO
25
Ltd.
2017-25A
D2R2,
CME
Term
SOFR
3
Month
+
4.4500%,
8.7790%,
7/18/38
(144A)
4,500,000
4,547,039
Neuberger
Berman
Loan
Advisers
CLO
26
Ltd.
2017-26A
D1R,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4290%,
10/18/38
(144A)
2,000,000
2,005,676
Neuberger
Berman
Loan
Advisers
CLO
30
Ltd.
2018-30A
D1R2,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1255%,
1/20/39
(144A)
5,250,000
5,257,059
Neuberger
Berman
Loan
Advisers
CLO
42
Ltd.
2021-42A
DR,
CME
Term
SOFR
3
Month
+
2.5000%,
6.8178%,
7/16/36
(144A)
7,340,000
7,290,916
Neuberger
Berman
Loan
Advisers
CLO
44
Ltd.
2021-44A
DR,
CME
Term
SOFR
3
Month
+
2.6500%,
6.9678%,
10/16/35
(144A)
8,000,000
7,998,780
Neuberger
Berman
Loan
Advisers
CLO
46
Ltd.
2021-46A
DR,
CME
Term
SOFR
3
Month
+
2.6500%,
6.9755%,
1/20/37
(144A)
12,500,000
12,499,052
Neuberger
Berman
Loan
Advisers
CLO
48
Ltd.
2022-48A
D,
CME
Term
SOFR
3
Month
+
3.2000%,
7.5185%,
4/25/36
(144A)
3,325,000
3,346,608
Neuberger
Berman
Loan
Advisers
CLO
50
Ltd.
2022-50A
DR,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1690%,
7/23/36
(144A)
2,000,000
2,004,307
Oaktree
CLO
Ltd.
2021-1A
D2R,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4175%,
1/15/38
(144A)
6,000,000
6,003,841
Obra
CLO
1
Ltd.
2024-1A
D1,
CME
Term
SOFR
3
Month
+
3.4000%,
7.7255%,
1/20/38
(144A)
9,070,000
9,228,638
Ocean
Trails
CLO
8
2020-8A
DRR,
CME
Term
SOFR
3
Month
+
3.4000%,
7.7176%,
7/15/34
(144A)
2,500,000
2,516,783
OCP
Aegis
CLO
Ltd.
2023-29A
D1R,
CME
Term
SOFR
3
Month
+
2.5500%,
6.8755%,
1/20/36
(144A)
4,650,000
4,656,049
OCP
Aegis
CLO
Ltd.
2024-39A
D2,
CME
Term
SOFR
3
Month
+
4.1000%,
8.4178%,
1/16/37
(144A)
4,000,000
4,000,517
OCP
CLO
Ltd.
2021-23A
D1R,
CME
Term
SOFR
3
Month
+
2.7500%,
7.0724%,
1/17/37
(144A)
2,000,000
2,008,172
OCP
CLO
Ltd.
2021-23A
D2R,
CME
Term
SOFR
3
Month
+
3.9000%,
8.2224%,
1/17/37
(144A)
4,000,000
4,021,136
OCP
CLO
Ltd.
2019-17A
D1R2,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4255%,
7/20/37
(144A)
3,000,000
3,018,115
OCP
CLO
Ltd.
2024-33A
D2,
CME
Term
SOFR
3
Month
+
4.4000%,
8.7255%,
7/20/37
(144A)
2,300,000
2,314,550
OCP
CLO
Ltd.
2022-25A
D2R,
CME
Term
SOFR
3
Month
+
4.5000%,
8.8255%,
7/20/37
(144A)
3,750,000
3,760,964
Octagon
54
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.3116%,
7.6292%,
7/15/34
(144A)
6,750,000
6,753,134
Octagon
56
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.4616%,
7.7792%,
10/15/34
(144A)
2,000,000
1,994,146
Octagon
57
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.3616%,
7.6792%,
10/15/34
(144A)
7,750,000
7,784,897
Octagon
70
Alto
Ltd.
2023-1A
D,
CME
Term
SOFR
3
Month
+
4.0900%,
8.4155%,
10/20/36
(144A)
7,500,000
7,577,684
Octagon
75
Ltd.
2025-1A
D2,
CME
Term
SOFR
3
Month
+
3.6500%,
7.9820%,
1/22/38
(144A)
8,300,000
8,321,668
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
7
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Octagon
Investment
Partners
29
Ltd.
2016-1A
DR2,
CME
Term
SOFR
3
Month
+
3.3000%,
7.6290%,
7/18/39
(144A)
$
6,000,000
$
6,025,951
Octagon
Investment
Partners
44
Ltd.
2019-1A
DR,
CME
Term
SOFR
3
Month
+
3.5116%,
7.8292%,
10/15/34
(144A)
10,600,000
10,600,981
OHA
Credit
Funding
5
Ltd.
2020-5A
D1R,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2290%,
10/18/37
(144A)
1,000,000
1,003,545
OHA
Credit
Funding
7
Ltd.
2020-7A
D1R2,
CME
Term
SOFR
3
Month
+
2.7000%,
6.9638%,
7/19/38
(144A)
5,000,000
5,000,644
OHA
Credit
Funding
9
Ltd.
2021-9A
D2R,
CME
Term
SOFR
3
Month
+
4.2000%,
8.5255%,
10/19/37
(144A)
3,000,000
3,031,288
OHA
Credit
Partners
VII
Ltd.
2012-7A
D1R4,
CME
Term
SOFR
3
Month
+
2.5000%,
6.8220%,
2/20/38
(144A)
18,725,000
18,771,260
Orchard
Park
CLO
Ltd.
2024-1A
D1,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2755%,
10/20/37
(144A)
1,000,000
1,004,262
Palmer
Square
CLO
Ltd.
2022-3A
D1R,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2755%,
7/20/37
(144A)
4,030,000
4,041,392
Palmer
Square
CLO
Ltd.
2024-4A
D1,
CME
Term
SOFR
3
Month
+
2.6500%,
6.9676%,
1/15/38
(144A)
2,500,000
2,512,490
Palmer
Square
CLO
Ltd.
2021-1A
C1R,
CME
Term
SOFR
3
Month
+
2.7000%,
7.0255%,
4/20/38
(144A)
6,750,000
6,750,610
Peace
Park
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.2116%,
7.5371%,
10/20/34
(144A)
4,750,000
4,778,555
Point
Au
Roche
Park
CLO
Ltd.
2021-1A
D,
CME
Term
SOFR
3
Month
+
3.0616%,
7.3871%,
7/20/34
(144A)
8,950,000
8,985,378
Post
CLO
Ltd.
2022-1A
D,
CME
Term
SOFR
3
Month
+
3.2000%,
7.5255%,
4/20/35
(144A)
5,750,000
5,753,180
Post
CLO
VI
Ltd.
2024-2A
D2,
CME
Term
SOFR
3
Month
+
4.4000%,
8.7255%,
1/20/38
(144A)
2,000,000
2,015,491
PPM
CLO
2
Ltd.
2019-2A
DR2B,
CME
Term
SOFR
3
Month
+
5.5700%,
9.8878%,
4/16/37
(144A)
4,000,000
4,002,000
PPM
CLO
7
Ltd.
2024-7A
D1A,
CME
Term
SOFR
3
Month
+
3.6000%,
7.9255%,
7/20/37
(144A)
10,000,000
10,008,234
Rad
CLO
10
Ltd.
2021-10A
D,
CME
Term
SOFR
3
Month
+
3.0116%,
7.3306%,
4/23/34
(144A)
9,500,000
9,503,800
RAD
CLO
21
Ltd.
2023-21A
D1R,
CME
Term
SOFR
3
Month
+
2.6000%,
6.9185%,
1/25/37
(144A)
5,280,000
5,287,276
RAD
CLO
26
Ltd.
2024-26A
D2,
CME
Term
SOFR
3
Month
+
4.2500%,
8.5755%,
10/20/37
(144A)
2,250,000
2,252,731
RAD
CLO
27
Ltd.
2024-27A
D1,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1175%,
1/15/38
(144A)
5,000,000
5,014,552
RAD
CLO
28
Ltd.
2024-28A
D1,
CME
Term
SOFR
3
Month
+
2.8000%,
7.0626%,
4/20/38
(144A)
2,000,000
2,016,000
REESE
PARK
CLO
Ltd.
2020-1A
D2RR,
CME
Term
SOFR
3
Month
+
4.0000%,
8.3176%,
1/15/38
(144A)
7,500,000
7,567,896
Regatta
XVIII
Funding
Ltd.
2021-1A
D1R,
CME
Term
SOFR
3
Month
+
2.6000%,
6.9176%,
4/15/38
(144A)
27,400,000
27,424,282
Regatta
XXIV
Funding
Ltd.
2021-5A
D1R,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1255%,
1/20/38
(144A)
13,950,000
14,089,494
Riserva
CLO
Ltd.
2016-3A
DRR,
CME
Term
SOFR
3
Month
+
3.5116%,
7.8406%,
1/18/34
(144A)
7,250,000
7,253,413
Rockford
Tower
CLO
Ltd.
2021-2A
D,
CME
Term
SOFR
3
Month
+
3.5116%,
7.8371%,
7/20/34
(144A)
2,000,000
2,013,630
Rockford
Tower
CLO
Ltd.
2025-1A
D1,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2065%,
3/31/38
(144A)
1,000,000
1,006,589
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
8
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Rockford
Tower
CLO
Ltd.
2025-1A
D2,
CME
Term
SOFR
3
Month
+
3.9500%,
8.2065%,
3/31/38
(144A)
$
4,000,000
$
4,007,012
Romark
CLO
III
Ltd.
2019-3A
CR,
CME
Term
SOFR
3
Month
+
3.5616%,
7.8792%,
10/15/34
(144A)
10,500,000
10,558,143
Romark
CLO
V
Ltd.
2021-5A
D,
CME
Term
SOFR
3
Month
+
3.8916%,
8.2092%,
1/15/35
(144A)
7,000,000
7,004,901
RR
17
Ltd.
2021-17A
C,
CME
Term
SOFR
3
Month
+
3.2116%,
7.5292%,
7/15/34
(144A)
4,000,000
4,001,515
RR
7
Ltd.
2019-7A
D1B,
CME
Term
SOFR
3
Month
+
6.5000%,
10.8176%,
1/15/37
(144A)
5,000,000
5,024,031
Sagard-Halseypoint
CLO
9
Ltd.
2025-9A
D2,
CME
Term
SOFR
3
Month
+
4.5000%,
8.7821%,
4/20/38
(144A)
3,000,000
3,022,862
Sandstone
Peak
III
Ltd.
2024-1A
D1,
CME
Term
SOFR
3
Month
+
3.8500%,
8.1685%,
4/25/37
(144A)
6,750,000
6,801,083
Sandstone
Peak
Ltd.
2021-1A
DR,
CME
Term
SOFR
3
Month
+
3.3500%,
7.6676%,
10/15/34
(144A)
10,375,000
10,409,817
Signal
Peak
CLO
10
Ltd.
2021-10A
D1R,
CME
Term
SOFR
3
Month
+
2.9000%,
7.2187%,
1/24/38
(144A)
1,600,000
1,610,395
Signal
Peak
CLO
11
Ltd.
2024-11A
D1,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4290%,
7/18/37
(144A)
9,000,000
9,042,035
Silver
Point
CLO
6
Ltd.
2024-6A
D1,
CME
Term
SOFR
3
Month
+
3.3000%,
7.6175%,
10/15/37
(144A)
10,000,000
10,068,414
Sixth
Street
CLO
VIII
Ltd.
2017-8A
CR2,
CME
Term
SOFR
3
Month
+
2.9500%,
7.2755%,
10/20/34
(144A)
10,000,000
10,001,415
Sound
Point
CLO
2025R-1
Ltd.
2025-1RA
D1,
CME
Term
SOFR
3
Month
+
3.2500%,
7.5720%,
2/20/38
(144A)
17,100,000
17,183,711
Sound
Point
CLO
35
Ltd.
2022-35A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3138%,
4/26/38
(144A)
1,500,000
1,506,203
Symphony
CLO
36
Ltd.
2022-36A
D1R,
CME
Term
SOFR
3
Month
+
3.3000%,
7.5752%,
10/24/37
(144A)
2,500,000
2,506,921
TCW
CLO
Ltd.
2020-1A
DR3,
CME
Term
SOFR
3
Month
+
3.4000%,
7.7255%,
4/20/34
(144A)
5,000,000
5,010,507
TCW
CLO
Ltd.
2022-1A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
1/20/38
(144A)
4,000,000
4,029,977
TCW
CLO
Ltd.
2019-2A
D1R2,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
1/20/38
(144A)
4,000,000
4,009,017
TCW
CLO
Ltd.
2021-1A
D1R1,
CME
Term
SOFR
3
Month
+
3.1000%,
7.4255%,
1/20/38
(144A)
16,000,000
16,034,723
Thompson
Park
CLO
Ltd.
2021-1A
DR,
CME
Term
SOFR
3
Month
+
2.7000%,
7.0175%,
4/15/34
(144A)
9,355,000
9,355,388
TRESTLES
CLO
III
Ltd.
2020-3A
D1R,
CME
Term
SOFR
3
Month
+
3.1500%,
7.4755%,
10/20/37
(144A)
3,900,000
3,926,330
Trinitas
CLO
XVI
Ltd.
2021-16A
D,
CME
Term
SOFR
3
Month
+
3.5616%,
7.8871%,
7/20/34
(144A)
2,250,000
2,265,417
Trinitas
CLO
XX
Ltd.
2022-20A
D1R,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
7/20/35
(144A)
4,000,000
4,008,021
Venture
44
CLO
Ltd.
2021-44A
D1,
CME
Term
SOFR
3
Month
+
3.4916%,
7.8171%,
10/20/34
(144A)
2,000,000
2,012,169
Voya
CLO
Ltd.
2018-3A
D,
CME
Term
SOFR
3
Month
+
3.2616%,
7.5792%,
10/15/31
(144A)
5,225,000
5,240,355
Voya
CLO
Ltd.
2021-1A
DR,
CME
Term
SOFR
3
Month
+
2.8000%,
7.1175%,
7/15/34
(144A)
11,500,000
11,491,432
Voya
CLO
Ltd.
2019-4A
DR,
CME
Term
SOFR
3
Month
+
3.4616%,
7.7792%,
1/15/35
(144A)
1,250,000
1,256,241
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
9
Shares/
Principal
Amounts
Value
Collateralized
Loan
Obligations
-
(continued)
Voya
CLO
Ltd.
2020-3A
D1RR,
CME
Term
SOFR
3
Month
+
2.7000%,
7.0255%,
1/20/38
(144A)
$
1,570,000
$
1,572,494
Voya
CLO
Ltd.
2024-7A
D1,
CME
Term
SOFR
3
Month
+
2.8500%,
7.1755%,
1/20/38
(144A)
1,550,000
1,554,616
Warwick
Capital
CLO
4
Ltd.
2024-4A
D1,
CME
Term
SOFR
3
Month
+
3.0000%,
7.3255%,
7/20/37
(144A)
4,650,000
4,684,512
Warwick
Capital
CLO
5
Ltd.
2024-5A
E,
CME
Term
SOFR
3
Month
+
5.5000%,
9.8255%,
1/20/38
(144A)
4,000,000
4,059,212
Wellfleet
CLO
Ltd.
2021-4A
D,
CME
Term
SOFR
3
Month
+
3.4416%,
7.7601%,
4/25/34
(144A)
6,600,000
6,639,731
Total
Collateralized
Loan
Obligations
(cost
$1,275,357,171)
1,277,140,557
Exchange
Traded
Funds
-
4
.9
%
Invesco
Senior
Loan
ETF
#
1,681,525
35,194,318
Janus
Henderson
AAA
CLO
ETF
£
607,419
30,850,811
66,045,129
Total
Exchange
Traded
Funds
(cost
$65,664,772)
66,045,129
Investment
Companies
-
1
.2
%
Money
Market
Funds
-
1
.2
%
Janus
Henderson
Cash
Liquidity
Fund
LLC,
4.3597%
£,∞
(cost
$16,830,329)
16,830,329
16,833,695
Investments
Purchased
with
Cash
Collateral
from
Securities
Lending
-
0.0
%
Investment
Companies
-
0.0
%
Janus
Henderson
Cash
Collateral
Fund
LLC,
4.2961%
£,∞
15,480
15,480
Time
Deposits
-
0.0
%
Royal
Bank
of
Canada,
4.3100%,
8/1/25
3,870
3,870
Total
Investments
Purchased
with
Cash
Collateral
from
Securities
Lending
(cost
$19,350)
19,350
Total
Investments
(total
cost
$
1,357,871,622
)
-
99
.9
%
1,360,038,731
Cash,
Receivables
and
Other
Assets,
net
of
Liabilities
-
0.1%
1,303,571
Net
Assets
-
100.0%
$1,361,342,302
Summary
of
Investments
by
Country
-
(Long
Positions)
(unaudited)
Country
Value
%
of
Investment
Securities
United
States
$
1,360,038,731
100
.0
%
Janus
Henderson
B-BBB
CLO
ETF
Schedule
of
Investments
(unaudited)
July
31,
2025
10
Schedule
of
Affiliated
Investments
-
(%
of
Net
Assets)
Affiliated
Investments,
at
Value
at
10/31/24
Purchases
Sales
Proceeds
Realized
Gain/(Loss)
Change
in
Unrealized
Appreciatio
n/
(Depreciation)
Affiliated
Investments,
at
Value
at
7/31/25
.............
Shares
Held
at
7/31/25
Dividend
Income
Investment
Company
-
3.5%
Exchange
Traded
Fund
-
2.3%
Janus
Henderson
AAA
CLO
ETF
$
$
126,905,210
$
(
96,480,342
)
$
139,909
$
286,034
$
30,850,811
607,419
$
956,982
Money
Market
Funds
-
1.2%
Janus
Henderson
Cash
Liquidity
Fund
LLC,
4.3597%
8,960,001
960,046,949
(
952,173,682
)
(
2,938
)
3,365
16,833,695
16,830,329
957,791
Investments
Purchased
with
Cash
Collateral
from
Securities
Lending
-
0.0%
Investment
Companies
-
0.0%
Janus
Henderson
Cash
Collateral
Fund
LLC,
4.2961%
47,642,529
(
47,627,049
)
15,480
15,480
61,070
Δ
Total
Affiliated
Investments
-
3.5%
$8,960,001
$1,134,594,688
$(1,096,281,073)
$136,971
$289,399
$47,699,986
$1,975,843
Janus
Henderson
B-BBB
CLO
ETF
Notes
to
Schedule
of
Investments
and
Other
Information
(unaudited)
July
31,
2025
11
CME
Chicago
Mercantile
Exchange
ETF
Exchange
Traded
Fund
LLC
Limited
Liability
Company
SOFR
Secured
Overnight
Financing
Rate
#
Loaned
security;
a
portion
of
the
security
is
on
loan
at
July
31,
2025.
Rate
shown
is
the
7-day
yield
as
of
July
31,
2025.
£
The
Fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
Investment
Company
Act
of
1940,
as
amended,
an
affiliated
company
is
one
in
which
the
Fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
which
is
under
common
ownership
or
control.
Δ
Net
of
income
paid
to
the
securities
lending
agent
and
rebates
paid
to
the
borrowing
counterparties.
Variable
or
floating
rate
security.
Rate
shown
is
the
current
rate
as
of
July
31,
2025.
Certain
variable
rate
securities
are
not
based
on
a
published
reference
rate
and
spread;
they
are
determined
by
the
issuer
or
agent
and
current
market
conditions.
Reference
rate
is
as
of
reset
date
and
may
vary
by
security,
which
may
not
indicate
a
reference
rate
and/or
spread
in
their
description.
144A
Securities
sold
under
Rule
144A
of
the
Securities
Act
of
1933,
as
amended,
are
subject
to
legal
and/or
contractual
restrictions
on
resale
and
may
not
be
publicly
sold
without
registration
under
the
1933
Act.
Unless
otherwise
noted,
these
securities
have
been
determined
to
be
liquid
in
accordance
with
the
requirements
of
Rule
22e-4,
under
the
1940
Act.
The
total
value
of
144A
securities
as
of
the
period
ended
July
31,
2025
is
$1,277,140,557
which
represents
93.8%
of
net
assets.
The
following
is
a
summary
of
the
inputs
that
were
used
to
value
the
Fund's
investments
in
securities
and
other
financial
instruments
as
of
July
31,
2025
.
See
Notes
to
Financial
Statements
for
more
information.
Valuation
Inputs
Summary
Level
1
-
Quoted
Prices
Level
2
-
Other
Significant
Observable
Inputs
Level
3
-
Significant
Unobservable
Inputs
Total
Assets
Investments
in
Securities:
Collateralized
Loan
Obligations
$
$
1,277,140,557
$
$
1,277,140,557
Exchange
Traded
Funds
66,045,129
66,045,129
Investment
Companies
16,833,695
16,833,695
Investments
Purchased
with
Cash
Collateral
from
Securities
Lending
19,350
19,350
Total
Assets
$
66,045,129
$
1,293,993,602
$
$
1,360,038,731
Janus
Henderson
B-BBB
CLO
ETF
12
Investment
Valuation 
Fund holdings
are
valued
in
accordance
with
policies
and
procedures
established
by
the
Adviser
pursuant
to
Rule
2a-5
under
the
1940
Act
and
approved
by
and
subject
to
the
oversight
of
the
Trustees
(the
“Valuation
Procedures”).
Equity
securities,
including
shares
of
exchange-traded
funds,
traded
on
a
domestic
securities
exchange
are
generally
valued
at
readily
available
market
quotations,
which
are
(i)
the
official
close
prices
or
(ii)
last
sale
prices
on
the
primary
market
or
exchange
in
which
the
securities
trade.
If
such
price
is
lacking
for
the
trading
period
immediately
preceding
the
time
of
determination,
such
securities
are
generally
valued
at
their
current
bid
price.
Equity
securities
that
are
traded
on
a
foreign
exchange
are
generally
valued
at
the
closing
prices
on
such
markets.
In
the
event
that
there
is
no
current
trading
volume
on
a
particular
security
in
such
foreign
exchange,
the
bid
price
from
the
primary
exchange
is
generally
used
to
value
the
security.
Foreign
securities
and
currencies
are
converted
to
U.S.
dollars
using
the
current
spot
USD
dollar
exchange
rate
in
effect
at
the
close
of
the
London
Stock
Exchange.
The Fund will
determine
the
market
value
of
individual
securities
held
by
it
by
using
prices
provided
by
one
or
more
approved
professional
pricing
services
or,
as
needed,
by
obtaining
market
quotations
from
independent
broker-dealers.
Most
debt
securities
are
valued
in
accordance
with
the
evaluated
bid
price
supplied
by
the
Adviser-approved
pricing
service
that
is
intended
to
reflect
market
value.
The
evaluated
bid
price
supplied
by
the
pricing
service
is
an
evaluation
that
may
consider
factors
such
as
security
prices,
yields,
maturities
and
ratings.
Certain
short-term
securities
maturing
within
60
days
or
less
may
be
evaluated
and
valued
on
an
amortized
cost
basis
provided
that
the
amortized
cost
determined
approximates
market
value.
Securities
for
which
market
quotations
or
evaluated
prices
are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
determined
in
good
faith
by
the
Adviser
pursuant
to
the
Valuation
Procedures. Circumstances
in
which
fair
valuation
may
be
utilized
include,
but
are
not
limited
to:
(i)
a
significant
event
that
may
affect
the
securities
of
a
single
issuer,
such
as
a
merger,
bankruptcy,
or
significant
issuer-specific
development;
(ii)
an
event
that
may
affect
an
entire
market,
such
as
a
natural
disaster
or
significant
governmental
action;
(iii)
a
nonsignificant
event
such
as
a
market
closing
early
or
not
opening,
or
a
security
trading
halt;
and
(iv)
pricing
of
a
non-valued
security
and
a
restricted
or
nonpublic
security.
Special
valuation
considerations
may
apply
with
respect
to
“odd-lot”
fixed-income
transactions
which,
due
to
their
small
size,
may
receive
evaluated
prices
by
pricing
services
which
reflect
a
large
block
trade
and
not
what
actually
could
be
obtained
for
the
odd-
lot
position.
The
value
of
the
securities
of
mutual
funds
held
by
the
Fund,
if
any,
will
be
calculated
using
the
NAV
of
such
mutual
funds,
and
the
prospectuses
for
such
mutual
funds
explain
the
circumstances
under
which
they
use
fair
valuation
and
the
effects
of
using
fair
valuation.
The
value
of
the
securities
of
any
cash
management
pooled
investment
vehicles
that
operate
as
money
market
funds
held
by
the
Fund,
if
any,
will
be
calculated
using
the
NAV
of
such
funds.
Valuation
Inputs
Summary 
FASB
ASC
820,
Fair
Value
Measurements
and
Disclosures
(“ASC
820”),
defines
fair
value,
establishes
a
framework
for
measuring
fair
value,
and
expands
disclosure
requirements
regarding
fair
value
measurements.
This
standard
emphasizes
that
fair
value
is
a
market-based
measurement
that
should
be
determined
based
on
the
assumptions
that
market
participants
would
use
in
pricing
an
asset
or
liability
and
establishes
a
hierarchy
that
prioritizes
inputs
to
valuation
techniques
used
to
measure
fair
value.
These
inputs
are
summarized
into
three
broad
levels: 
Level
1
Unadjusted
quoted
prices
in
active
markets
the
Fund
has
the
ability
to
access
for
identical
assets
or
liabilities.
Level
2
Observable
inputs
other
than
unadjusted
quoted
prices
included
in
Level
1
that
are
observable
for
the
asset
or
liability
either
directly
or
indirectly.
These
inputs
may
include
quoted
prices
for
the
identical
instrument
on
an
inactive
market,
prices
for
similar
instruments,
interest
rates,
prepayment
speeds,
credit
risk,
yield
curves,
default
rates
and
similar
data.
Assets
or
liabilities
categorized
as
Level
2
in
the
hierarchy
generally
include:
debt
securities
fair
valued
in
accordance
with
the
evaluated
bid
or
ask
prices
supplied
by
a
pricing
service;
securities
traded
on
OTC
markets
and
listed
securities
for
which
no
sales
are
reported
that
are
fair
valued
at
the
latest
bid
price
(or
yield
equivalent
thereof)
obtained
from
one
or
more
dealers
transacting
in
a
market
for
such
securities
or
by
a
pricing
service
approved
by
the
Fund’s
Trustees;
and
certain
short-term
debt
securities
with
maturities
of
60
days
or
less
that
are
fair
valued
at
amortized
cost.
Other
securities
that
may
be
categorized
as
Level
2
in
the
hierarchy
include,
but
are
not
limited
Janus
Henderson
B-BBB
CLO
ETF
13
to,
preferred
stocks,
bank
loans,
swaps,
investments
in
unregistered
investment
companies,
options,
and
forward
contracts.
Level
3
Unobservable
inputs
for
the
asset
or
liability
to
the
extent
that
relevant
observable
inputs
are
not
available,
representing
the
Fund’s
own
assumptions
about
the
assumptions
that
a
market
participant
would
use
in
valuing
the
asset
or
liability,
and
that
would
be
based
on
the
best
information
available.
The
inputs
or
methodology
used
for
fair
valuing
securities
are
not
necessarily
an
indication
of
the
risk
associated
with
investing
in
those
securities.
The
summary
of
inputs
used
as
of
July
31,
2025 to
fair
value
the
Fund’s
investments
in
securities
and
other
financial
instruments
is
included
in
the
“Valuation
Inputs
Summary”
in
the
Notes
to
Schedule
of
Investments
and
Other
Information.
For
additional
information
on
the
Fund,
please
refer
to
the
Fund's
most
recent
semiannual
or
annual
financial
statements.
125-35-70447
09-25